Combination of sedating and non sedating antihistamines
The concentration of alpha -adrenergic agonists in the combination may range from 0.001% to 0.2%.
The concentration of phenylephrine may however range from 0,01% to 15%, its preferred concentration is between 0.1% to 2%.
Based on the ICAM-1(rhinovirus binding site) down-regulating effect of azelastine, it may be particularly useful in the treatment of common cold/flu. With regard to allergic diseases and common cold, either topical or oral alpha -adrenergic agonists are used as disclosed in WO 94/ 08551. pseudoephedrine, phenylephrine, phenylpropanolamine as disclosed in, for example, WO 92/ 04021, WO 92/ 04022, WO 94/ 08550, WO 94/ 14449 and WO 95/ 23591) carry the risk of inducing systemic adverse effects such as tachycardia, increased blood pressure, and CNS stimulation (e.g. Topical alpha -adrenergic agonists such as epinephrine, fenoxazoline, indanazoline, naphazoline, oxedrine, oxymetazoline, phenylephrine, tefazoline, tetryzoline, tramazoline, tymazoline, xylometazoline are used as local decongestants in patients with allergic or vasomotor rhinitis, conjunctivitis or with upper respiratory infections (e.g.Nasal blockage is the result of the pooling of blood in the capacitance vessels of the mucosa, and to some degree the result of tissue oedema.Patients with allergic conjunctivitis show similar symptoms.Detailed description of the invention The antiallergic component in the pharmaceutical combination of the present invention includes a non-sedating antihistamine applied topically as for instance acrivastine, antazoline, astemizole, azelastine cetirizine, ebastine, efletirizine, epinastine, fexofenadine, loratidine, levocabastine, mizolastine, oxatomide, setastine, temelastine or terfenadine or a pharmaceutically acceptable salt thereof.Azelastine is a histamine H1-receptor antagonist of the second generation without sedating effect.